Craniopharyngioma
Recent clinical, regulatory, research and industry developments relating to this disease.
Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults
- Q2 2027Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- Q4 2027Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Clinical MilestonesViewHide
- 2026-04-23Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous CraniopharyngiomaResults expected Q4 2027
- 2026-04-23Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young AdultsResults expected Q1 2027
- 2026-04-08Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaResults expected Q2 2027
- 2026-04-20Safety and Efficacy of Anlotinib in the Treatment of Recurrent CraniopharyngiomaPrimary completion
- 2026-06-23ClinicalMemantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot StudyResults posted
- 2026-06-10ClinicalPhase II Trial of BRAF/MEK Inhibitors in Papillary CraniopharyngiomasResults posted
- 2026-04-23ClinicalPhase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous CraniopharyngiomaResults expected Q4 2027
- 2026-04-23ClinicalTovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young AdultsResults expected Q1 2027
- 2026-04-20ClinicalSafety and Efficacy of Anlotinib in the Treatment of Recurrent CraniopharyngiomaPrimary completion
- 2026-04-08ClinicalPhase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaResults expected Q2 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Craniopharyngioma1
- Pituitary Neoplasms1
Leading journals1
- Journal of internal medicine1
Leading researchers1
- Erfurth EM1
Affiliations (unnormalised)1
- Skåne University Hospital1
Reference
Authoritative identity, definition & identifiers.
A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.